

Amino Acid Sequence Disclosures, please amend the above-identified application as follows.

In the specification:

Please replace pages 2, 3, 4, 7, 8, 10-19, 21-23, 26-35, 37, 40-42, 45, 57, 59, 65, 68-75, 81, 83, 84, 86-93, and 95-97 with the substitute pages submitted herewith.

In the Claims:

Please amend claims 15, 24-26, 29, 34, 36 and 48 as follows:

15. (Amended) A peptide according to claim 13, selected from;

DFYHSKRRLIFS	(SEQ ID No. 4)
TDFYHSKRRLIF,	(SEQ ID No. 5)
AFYHSKRRLIFS,	(SEQ ID No. 6)
DAYHSKRRLIFS,	(SEQ ID No. 7)
DFAHSKRRLIFS,	(SEQ ID No. 8)
DFYASKRRLIFS,	(SEQ ID No.9)
DFYHAKRRLIFS,	(SEQ ID No.10)
DFYHSARRLIFS,	(SEQ ID No.11)
DFYHSKRRLIFS,	(SEQ ID No.12)
DFYHSKRRLAFS,	(SEQ ID No.13)
DFYHSKRRLIFA,	(SEQ ID No.14)
FYHSKRRLIFS,	(SEQ ID No.15)
YHSKRRLIFS,	(SEQ ID No. 16)
HSKRRLIFS,	(SEQ ID No. 17)
DFYHSKRRLIF,	(SEQ ID No. 18)
FYHSKRRLIF	(SEQ ID No. 19)
YHSKRRLIF	(SEQ ID No. 20)
HSKRRLIF,	(SEQ ID No. 21)

S K R R L I F, (SEQ ID No. 22)

K R R L I F, (SEQ ID No. 23)

H- Arg- Leu- Ile- Phe -NH2 (SEQ ID No. 24)

H- Arg- Arg- Leu- Ile- Phe -NH2 (SEQ ID No. 25)

H- Lys- Arg- Arg- Leu- Ile- Phe -NH2 (SEQ ID No. 26)

H- Ala- Lys- Arg- Arg- Leu- Ile- Phe -NH2 (SEQ ID No. 27)

H- His- Ala- Lys- Arg- Arg- Leu- Ile- Phe -NH2 (SEQ ID No. 28)

H- Asn- Leu- Phe- Gly -NH2 (SEQ ID No. 29)

H- Arg- Asn- Leu- Phe- Gly -NH2 (SEQ ID No. 30)

H- Abu- Arg- Asn- Leu- Phe- Gly -NH2 (SEQ ID No. 31)

H- Ala- Abu- Arg- Asn- Leu- Phe- Gly -NH2 And (SEQ ID No. 32)

H- Ser- Ala- Abu- Arg- Asn- Leu- Phe- Gly -NH2 (SEQ ID No. 33)

24. (Amended) A peptide according to claim 16, wherein X₅ is isoleucine.

25. (Amended) A peptide according to claim 20, selected from the group consisting of:

H S K R R L I F (SEQ ID No. 34)

H A K R R L I F (SEQ ID No. 35)

H S K R R L F G (SEQ ID No. 36)

H A K R R L F G (SEQ ID No. 37)

K A C R R L F G (SEQ ID No. 38)

K A C R R L I F (SEQ ID No. 39)

	X1	X2	X3	R	X4	L	X5	F		
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 28)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 40)
	H-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 41)
H-	Pya-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 42)
H-	Thi-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 43)
H-	Hse-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 44)
H-	Phe-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 45)
H-	Dab-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 46)
H-	His-	Gly-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 47)
H-	His-	Abu-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 48)
H-	His-	Nva-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 49)
H-	His-	Bug-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 50)
H-	His-	Val-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2	(SEQ ID No. 51)

H-	His-	Ile-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 52)
H-	His-	Phg-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 53)
H-	His-	Phe-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 54)
H-	His-	Ala-	Ala-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 56)
H-	His-	Ala-	Nle-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 57)
H-	His-	Ala-	Abu-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 58)
H-	His-	Ala-	Leu-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 59)
H-	His-	Ala-	Arg-	Arg-	Arg-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 60)
H-	His-	Ala-	Lys-	Ala-	Arg-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 61)
H-	His-	Ala-	Lys-	Cit-	Arg-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 62)
H-	His-	Ala-	Lys-	Hse-	Arg-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 63)
H-	His-	Ala-	Lys-	His-	Arg-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 64)
H-	His-	Ala-	Lys-	Nle-	Arg-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 65)
H-	His-	Ala-	Lys-	Gln-	Arg-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 66)
H-	His-	Ala-	Lys-	Lys-	Arg-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 67)
H-	His-	Ala-	Lys-	Arg-	Ala-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 68)
H-	His-	Ala-	Lys-	Arg-	Asn-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 69)
H-	His-	Ala-	Lys-	Arg-	Pro-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 70)
H-	His-	Ala-	Lys-	Arg-	Ser-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 71)
H-	His-	Ala-	Lys-	Arg-	Aib-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 72)
H-	His-	Ala-	Lys-	Arg-	Sar-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 73)
H-	His-	Ala-	Lys-	Arg-	Cit-	Leu-	Ile-	Phe	-NH2 (SEQ ID No. 74)
H-	His-	Ala-	Lys-	Arg-	Arg-	Ala-	Ile-	Phe	-NH2 (SEQ ID No. 76)
H-	His-	Ala-	Lys-	Arg-	Arg-	Ile-	Ile-	Phe	-NH2 (SEQ ID No. 77)
H-	His-	Ala-	Lys-	Arg-	Arg-	Ile-	Ile-	Phe	-NH2 (SEQ ID No. 78)
H-	His-	Ala-	Lys-	Arg-	Arg-	Val-	Ile-	Phe	-NH2 (SEQ ID No. 79)
H-	His-	Ala-	Lys-	Arg-	Arg-	Nle-	Ile-	Phe	-NH2 (SEQ ID No. 80)
H-	His-	Ala-	Lys-	Arg-	Arg-	Nva-	Ile-	Phe	-NH2 (SEQ ID No. 81)
H-	His-	Ala-	Lys-	Arg-	Arg-	Cha-	Ile-	Phe	-NH2 (SEQ ID No. 82)
H-	His-	Ala-	Lys-	Arg-	Arg-	Phe-	Ile-	Phe	-NH2 (SEQ ID No. 83)
H-	His-	Ala-	Lys-	Arg-	Arg-	1Nap-	Ile-	Phe	-NH2 (SEQ ID No. 84)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ala-	Phe	-NH2 (SEQ ID No. 85)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Leu-	Phe	-NH2 (SEQ ID No. 86)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Val-	Phe	-NH2 (SEQ ID No. 87)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Nle-	Phe	-NH2 (SEQ ID No. 88)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Nva-	Phe	-NH2 (SEQ ID No. 89)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Cha-	Phe	-NH2 (SEQ ID No. 90)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Phe-	Phe	-NH2 (SEQ ID No. 91)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	1Nap-	Phe	-NH2 (SEQ ID No. 92)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Phe	Phe	-NH2 (SEQ ID No. 93)

H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Leu	-NH2	(SEQ ID No. 95)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Cha	-NH2	(SEQ ID No. 96)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Hof	-NH2	(SEQ ID No. 97)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Tyr	-NH2	(SEQ ID No. 98)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 99)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	mFPhe	-NH2	(SEQ ID No. 100)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Trp	-NH2	(SEQ ID No. 101)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	1Nap	-NH2	(SEQ ID No. 102)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	2Nap	-NH2	(SEQ ID No. 103)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Lys	-NH2	(SEQ ID No. 104)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Tic	-NH2	(SEQ ID No. 105)
H-	His	Ala	Lys	Arg	Arg	Leu	Ile	L-Pse	OH	(SEQ ID No. 106)
H-	His	Ala	Lys	Arg	Arg	Leu	Ile	D-Pse	OH	(SEQ ID No. 107)
H-	His	Ser	Lys	Arg	Arg	Leu	Ile	L-Pse	OH	(SEQ ID No. 108)
H-	His	Ser	Lys	Arg	Arg	Leu	Ile	D-Pse	OH	(SEQ ID No. 109)
H-	His	Ala	Lys	Arg	Arg	Leu	Ile	L-Psa	OH	(SEQ ID No. 110)
H-	His	Ala	Lys	Arg	Arg	Leu	Ile	D-Psa	OH	(SEQ ID No. 111)
H-	His	Ser	Lys	Arg	Arg	Leu	Ile	L-Psa	OH	(SEQ ID No. 112)
H-	His	Ser	Lys	Arg	Arg	Leu	Ile	D-Psa	OH	(SEQ ID No. 113)
H-	His	Ala	Lys	Arg	Arg	Leu	Ile	Dhp	OH	(SEQ ID No. 114)
H-	His	Ser	Lys	Arg	Arg	Leu	Ile	Dhp	OH	(SEQ ID No. 115)
H-	His	Ala	Lys	Arg	Arg	Leu	Ile	Pheol		(SEQ ID No. 116)
H-	His	Ser	Lys	Arg	Arg	Leu	Ile	Pheol		(SEQ ID No. 117)
H-	Ala-	Ala-	Abu-	Arg-	Arg-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 118)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 119)
H-	Ala-	Ala-	Lys-	Arg-	Cit-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 120)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ala-	pFPhe	-NH2	(SEQ ID No. 121)
H-	Ala-	Ala-	Abu-	Arg-	Ser-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 122)
H-	Ala-	Ala-	Lys-	Gln-	Arg-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 123)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 124)
H-	Gly-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 125)
H-	Ala-	Ala-	Lys-	hArg-	Arg-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 126)
H-	Ala-	Ala-	Lys-	Ser-	Arg-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 127)
H-	Ala-	Ala-	Lys-	Hse-	Arg-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 128)
H-	Ala-	Ala-	Lys-	Arg-	Lys-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 129)
H-	Ala-	Ala-	Lys-	Arg-	Orn-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 130)
H-	Ala-	Ala-	Lys-	Arg-	Gln-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 131)
H-	Ala-	Ala-	Lys-	Arg-	Hse-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 132)
H-	Ala-	Ala-	Lys-	Arg-	Thr-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 133)
H-	Ala-	Ala-	Lys-	Arg-	Nva-	Leu-	Ile-	pFPhe	-NH2	(SEQ ID No. 134)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Phg-	Ile-	pFPhe	-NH2	(SEQ ID No. 135)

H-	Ala-	Ala-	Lys-	Arg-	Arg-	Met-	Ile-	pFPhe	-NH2	(SEQ ID No. 136)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Ala-	Ile-	pFPhe	-NH2	(SEQ ID No. 137)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Hof-	Ile-	pFPhe	-NH2	(SEQ ID No. 138)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	hLeu-	Ile-	pFPhe	-NH2	(SEQ ID No. 139)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	alle-	Ile-	pFPhe	-NH2	(SEQ ID No. 140)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Gly-	pFPhe	-NH2	(SEQ ID No. 141)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	βAla	pFPhe	-NH2	(SEQ ID No. 142)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Phg-	pFPhe	-NH2	(SEQ ID No. 143)
H ⁱ	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Aib-	pFPhe	-NH2	(SEQ ID No. 144)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Sar-	pFPhe	-NH2	(SEQ ID No. 145)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Pro-	pFPhe	-NH2	(SEQ ID No. 146)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Bug-	pFPhe	-NH2	(SEQ ID No. 147)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ser-	pFPhe	-NH2	(SEQ ID No. 148)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Asp-	pFPhe	-NH2	(SEQ ID No. 149)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Asn-	pFPhe	-NH2	(SEQ ID No. 150)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	pFPhe-	Phe	-NH2	(SEQ ID No. 151)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	diClPhe	Phe	-NH2	(SEQ ID No. 152)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	pClPhe-	Phe	-NH2	(SEQ ID No. 153)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	mClPhe	Phe	-NH2	(SEQ ID No. 154)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	oClPhe-	Phe	-NH2	(SEQ ID No. 155)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	pIPhe-	Phe	-NH2	(SEQ ID No. 156)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	TyrMe-	Phe	-NH2	(SEQ ID No. 157)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Thi-	Phe	-NH2	(SEQ ID No. 158)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Pya-	Phe	-NH2	(SEQ ID No. 159)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	diClPhe	-NH2	(SEQ ID No. 160)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	pClPhe	-NH2	(SEQ ID No. 161)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	mClPhe	-NH2	(SEQ ID No. 162)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	oClPhe	-NH2	(SEQ ID No. 163)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phg	-NH2	(SEQ ID No. 164)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	TyrMe	-NH2	(SEQ ID No. 165)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Thi	-NH2	(SEQ ID No. 166)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Pya	-NH2	(SEQ ID No. 167)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Inc	-NH2	(SEQ ID No. 168)

and the cyclic peptides:

5,8-cyclo-[H-His-Ala-Lys-Arg-Lys-Leu-Phe-Gly]

(SEQ ID No. 169)

5,8-cyclo-[H-His-Ala-Lys-Arg-Orn-Leu-Phe-Gly]

(SEQ ID No. 170)

26. (Amended) A peptide of the formula III or IV;

$H'X_2K'R_1R_2L'X_5F$ (formula III) (SEQ ID No. 3) or $H'X_2K'R_1R_2L'FX_5$ (formula IV) (SEQ ID No. 189)

or a variant thereof, wherein

H' is nothing, His, D-His, Ala, Thi, Hse, Phe, or Dab;

X₂ is Ala, Ser, Abu, Val;

K' is Lys, Arg, or Abu;

R₁ is Arg, Lys, or Gln; and

R₂ is Arg, forms a cyclic peptide with the C-terminal residue, Ser, or Cit;

L' is Leu or Ile;

X₅ is Ile, Leu, Gly, or Ala; and

F' is Phe, para-fluoroPhe, meta-fluoroPhe, L-Psa, 2-Nap,Dhp, or D-Psa.

29. (Amended) A peptide according to claim 26 of the formula IV

$H'X_2K'R_1R_2L'F'X_5$ (SEQ ID No. 189).

34. (Amended) A peptide according to claim 26 selected from the group consisting of:

H-	his-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH ₂	(SEQ ID No. 171)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH ₂	(SEQ ID No. 172)
	H-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH ₂	(SEQ ID No. 173)
H-	Thi-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH ₂	(SEQ ID No. 174)
H-	Hse-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH ₂	(SEQ ID No. 175)
H-	Phe-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH ₂	(SEQ ID No. 176)
H-	Dab-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH ₂	(SEQ ID No. 177)
H-	His-	Abu-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH ₂	(SEQ ID No. 178)
H-	His-	Val-	Lys-	Arg-	Arg-	Leu-	Ile-	Phe	-NH ₂	(SEQ ID No. 179)
H-	His-	Ala-	Arg-	Arg-	Arg-	Leu-	Ile-	Phe	-NH ₂	(SEQ ID No. 180)
H-	His-	Ala-	Lys-	Arg-	Arg-	Ile-	Ile-	Phe	-NH ₂	(SEQ ID No. 181)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Leu-	Phe	-NH ₂	(SEQ ID No. 182)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	pFPhe	-NH ₂	(SEQ ID No. 99)
H-	His-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	2Nap	-NH ₂	(SEQ ID No. 103)
H-	His	Ala	Lys	Arg	Arg	Leu	Ile	D-Psa	OH	(SEQ ID No. 116)
H-	His	Ser	Lys	Arg	Arg	Leu	Ile	Dhp	OH	(SEQ ID No. 117)
H-	Ala-	Ala-	Abu-	Arg-	Arg-	Leu-	Ile-	pFPhe	-NH ₂	(SEQ ID No. 118)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ile-	pFPhe	-NH ₂	(SEQ ID No. 119)
H-	Ala-	Ala-	Lys-	Arg-	Cit-	Leu-	Ile-	pFPhe	-NH ₂	(SEQ ID No. 120)
H-	Ala-	Ala-	Lys-	Arg-	Arg-	Leu-	Ala-	pFPhe	-NH ₂	(SEQ ID No. 121)
H-	Ala-	Ala-	Abu-	Arg-	Ser-	Leu-	Ile-	pFPhe	-NH ₂	(SEQ ID No. 122)
H-	Ala-	Ala-	Lys-	Gln-	Arg-	Leu-	Ile-	pFPhe	-NH ₂	(SEQ ID No. 123)
H-	Ala-	Lys-	Arg-	Arg-	Arg-	Leu-	Ile-	pFPhe	-NH ₂	(SEQ ID No. 183)

36. (Amended) An assay for the identification of compounds that interact with a cyclin or a cyclin when complexed with the physiologically relevant CDK, comprising;

(a) incubating a candidate compound and peptide of formula I;

$X_1X_2X_3RX_4LX_5F$ (formula II) (SEQ ID No. 2)

wherein X_1 , X_3 , X_4 and X_5 may be any amino acid and X_2 is serine or alanine; and variants thereof or a peptide of the formula III or IV:

$H'X'_2K'R_1R_2L'X'_5F'$ (formula III) (SEQ ID No. 3) or

$H'X'_2K'R_1R_2L'F'X'_5$ (formula IV) (SEQ ID No. 189) or a variant thereof,

wherein

H' is His, nothing, D-His, Ala, Thi, Hse, Phe, or Dab;

X'₂ is Ala, Ser, Abu, Val;

K' is Lys, Arg, or Abu;

R₁ is Arg, Lys, or Gln; and

R₂ is Arg, forms a cyclic peptide with the C-terminal residue, Ser, or Cit;

L' is Leu or Ile;

X'₅ is Ile, Leu, Gly, or Ala;

F' is Phe, para-fluoroPhe, meta-fluoroPhe, L-Psa, 2-Nap,Dhp, or D-Psa.

and a cyclin or cyclin/CDK complex;

(b) detecting binding of either the candidate compound or the peptide of formula II or III with cyclin.

48. (Amended) A method of using a cyclin in a drug screening assay comprising:

(a) selecting a candidate compound by performing rational drug design with a three-dimensional model of said cyclin, wherein said selecting is performed in conjunction with computer modeling;

(b) contacting the candidate compound with the cyclin; and

(c) detecting the binding affinity of the candidate compound for the cyclin groove; wherein a potential drug is selected on the basis of its having a greater affinity for the cyclin groove than that of a peptide of formula II;

X₁X₂X₃RX₄LX₅F (formula II) (SEQ ID No. 2)

wherein X₁, X₃, X₄ and X₅ may be any amino acid and X₂ is serine or alanine; and variants thereof or a peptide of formula III or IV:

H'X'₂K'R₁R₂L'X'₅F' (formula III) (SEQ ID No. 3) or

H'X'₂K'R₁R₂L'F'X'₅ (formula IV) (SEQ ID No.189) or a variant thereof,

wherein

H' is His, nothing, D-His, Ala, Thi, Hse, Phe, or Dab;

X'₂ is Ala, Ser, Abu, Val;

K' is Lys, Arg, or Abu;

R₁ is Arg, Lys, or Gln; and

R₂ is Arg, forms a cyclic peptide with the C-terminal residue, Ser, or Cit;

L' is Leu or Ile;

X'₅ is Ile, Leu, Gly, or Ala;

F' is Phe, para-fluoroPhe, meta-fluoroPhe, L-Psa, 2-Nap,Dhp, or D-Psa.